Goldman Sachs analyst Scott Fidel raised the firm’s price target on HCA Healthcare (HCA) to $520 from $470 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $525 from $444 at Cantor Fitzgerald
- HCA Healthcare price target raised to $500 from $400 at Oppenheimer
- HCA Healthcare price target raised to $505 from $475 at Mizuho
- HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy Uncertainties
- HCA Healthcare price target raised to $475 from $465 at KeyBanc